ARTV
HEALTHCAREArtiva Biotherapeutics, Inc. Common Stock
AI Insight
What's Moving ARTV Today?
No stock-specific AI insight has been generated for ARTV yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.47$14.53
$9.94
Fundamentals
Market Cap$455M
P/E Ratio—
EPS$-3.55
Dividend Yield—
Dividend / Share—
ROE-67.9%
Profit Margin—
Debt / Equity—
Trading
Volume105K
Avg Volume (10D)—
Shares Outstanding48.6M
ARTV News
25 articles- Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceYahoo Finance·Jun 23, 2026
- Ra capital funds acquire $7.65m in Artiva Biotherapeutics stockInvesting.com India·Jun 11, 2026
- Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast TodayYahoo Finance·Jun 8, 2026
- Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceYahoo Finance·May 28, 2026
- Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseasesTraders Union·May 20, 2026
- Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic DiseasesYahoo Finance·May 19, 2026
- Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and DevelopmentYahoo Finance·May 19, 2026
- Artiva: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA (NASDAQ:ARTV)Seeking Alpha·May 8, 2026
- Artiva Biotherapeutics Announces $300 Million Equity OfferingTipRanks·May 8, 2026
- Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·May 8, 2026
- Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business HighlightsYahoo Finance·May 8, 2026
- Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026Yahoo Finance·May 8, 2026
- Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobeNewswire Inc.·Apr 28, 2026
- Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Apr 17, 2026
- Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at NeedhamMarketbeat·Apr 15, 2026
- Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire Inc.·Apr 8, 2026
- Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Mar 10, 2026
- Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data UpdateMarketbeat·Mar 4, 2026
- Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 25, 2026
- Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement GrantYahoo Finance·Feb 24, 2026
- AtaiBeckley names Michael Faerm as finance chiefProactive Investors·Feb 19, 2026
- Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of DirectorsYahoo Finance·Feb 19, 2026
- Undervalued Penny Stocks To Consider In January 2026Yahoo Finance·Jan 26, 2026
- Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHLYahoo Finance·Jan 21, 2026
- Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO’s Latest Insider Share SaleYahoo Finance·Dec 19, 2025
All 25 articles loaded
Price Data
Open$9.90
Previous Close$9.80
Day High$10.28
Day Low$9.80
52 Week High$14.53
52 Week Low$1.47
52-Week Range
$1.47$14.53
$9.94
Fundamentals
Market Cap$455M
P/E Ratio—
EPS$-3.55
Dividend Yield—
Dividend / Share—
ROE-67.9%
Profit Margin—
Debt / Equity—
Trading
Volume105K
Avg Volume (10D)—
Shares Outstanding48.6M
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc. is an innovative biotechnology company specializing in the development of advanced cell therapies, particularly targeting cancer through its proprietary natural killer (NK) cell platform. The company boasts a robust pipeline addressing both hematologic and solid tumors, reflecting its dedication to innovation within the rapidly evolving immuno-oncology space. With a focus on scientific excellence and strategic partnerships, Artiva is well-positioned to drive significant advancements in cancer treatment, aiming to enhance patient outcomes as its clinical candidates progress through trials.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—